论文部分内容阅读
作者旨在测定tacrolimus(FK506)与盐酸西咪替丁在0.9%氯化钠注射液中的可配伍性.取5mg/ml FK506注射液1.0ml和150mg/ml盐酸西咪替丁注射液2ml置于500ml的容量瓶中,用0.9%氯化钠注射液加至500ml,使FK506和西咪替丁的浓度分别制成10和600μg/ml.将 FK506和盐酸西咪替丁注射液分别以0.9%氯化钠注射液稀释配成浓度与FK506-西咪替丁混合液相同的对照液,试样一式三份,贮存于22～26℃下.制备后于 0、1、2、4、8、12、24和48h取样对着光和黑色背景进行目测检查颜色变化,混浊和沉淀,同时采用HPLC法测定FK506和西咪替丁的浓度,其浓度至少应保持在初始浓度的90%则认为稳定.
The aim of the authors was to determine the compatibility of tacrolimus (FK506) with cimetidine hydrochloride in 0.9% sodium chloride injection by taking 1.0 ml of 5 mg / ml FK506 injection and 2 ml of 150 mg / ml cimetidine hydrochloride injection In a 500 ml volumetric flask, the concentration of FK506 and cimetidine was adjusted to 500 ml with a 0.9% sodium chloride injection at concentrations of 10 and 600 μg / ml respectively.The FK506 and cimetidine hydrochloride injections were administered at 0.9 % Sodium chloride injection dubbed dosing concentration and FK506-cimetidine mixture of the same control solution, the sample in triplicate, stored at 22 ~ 26 ° C after preparation at 0,1,2,4,8 , 12, 24, and 48h samples were visually examined for light and black background for color change, turbidity and sedimentation while the concentrations of FK506 and cimetidine were determined by HPLC at a concentration of at least 90% of the initial concentration stable.